Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease

被引:421
作者
Ferrario, Carlos M. [1 ]
Strawn, William B. [1 ]
机构
[1] Wake Forest Univ, Sch Med, Hypertens Vasc Dis Ctr, Winston Salem, NC 27109 USA
关键词
D O I
10.1016/j.amjcard.2006.01.059
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Inflammation is a key mechanism in the initiation, progression, and clinical sequelae of cardiovascular diseases (CVDs), including atherosclerosis, nephropathy, and cardiomyopathy. Angiotensin II, the major effector peptide of the renin-angiotensin-aldosterone system (RAAS), plays a significant role in the advent and perpetuation of these inflammatory diseases, most notably in atherogenesis. Consequently, suppression of the influence of angiotensin II by angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers may reduce or potentially reverse atherosclerosis and other inflammation-associated CVDs. Angiotensin II receptor blockers and angiotensin-converting enzyme inhibitors exert anti-inflammatory actions and prevent or reduce the development of atherosclerosis in animal models. Clinically, RAAS suppression reduces common carotid and femoral artery intima-media thickness, thus indicating moderation of the vascular disease process. These clinical benefits likely involve restraint of the deleterious effects of angiotensin II in addition to, or independent of, lowering blood pressure. Increasing evidence that the detection and monitoring of vascular inflammation are important tools in the management of atherosclerosis also implicates the RAAS in this pathogenic process. Inflammatory molecules such as intercellular adhesion molecule-1, vascular cell adhesion molecule-1, monocyte chemoattractant protein-1, tumor necrosis factor-alpha, and C-reactive protein have potential diagnostic and prognostic values in CVD and are modified by angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers. Monitoring these markers may be crucial for determining which agents, or combinations of agents, will result in the most clinically beneficial outcomes for patients. Large-scale trials are still required to determine the effects of the long-term suppression of inflammation on CVDs through the use of RAAS modulating agents, as well as to determine how closely markers of inflammatory activity may correlate with CVD outcomes. (c) 2006 Elsevier Inc. All rights reserved.
引用
收藏
页码:121 / 128
页数:8
相关论文
共 53 条
  • [1] [Anonymous], 1992, NEW ENGL J MED, V327, P685, DOI [DOI 10.1056/NEJM199209033271003, 10.1056/NEJM199209033271003.Erratumin]
  • [2] Transiently heightened angiotensin II has distinct effects on atherosclerosis and aneurysm formation in hyperlipidemic mice
    Ayabe, N
    Babaev, VR
    Tang, YW
    Tanizawa, T
    Fogo, AB
    Linton, MF
    Ichikawaa, I
    Fazio, S
    Kon, V
    [J]. ATHEROSCLEROSIS, 2006, 184 (02) : 312 - 321
  • [3] Stimulation of endothelial progenitor cells - A new putative therapeutic effect of angiotensin II receptor antagonists
    Bahlmann, FH
    de Groot, K
    Mueller, O
    Hertel, B
    Haller, H
    Fliser, D
    [J]. HYPERTENSION, 2005, 45 (04) : 526 - 529
  • [4] Inflammatory cytokines stimulated C-reactive protein production by human coronary artery smooth muscle cells
    Calabró, P
    Willerson, JT
    Yeh, ETH
    [J]. CIRCULATION, 2003, 108 (16) : 1930 - 1932
  • [5] A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure
    Cohn, JN
    Tognoni, G
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (23) : 1667 - 1675
  • [6] Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE):: a randomised trial against atenolol
    Dahlöf, B
    Devereux, RB
    Kjeldsen, SE
    Julius, S
    Beevers, G
    de Faire, U
    Fyhrquist, F
    Ibsen, H
    Kristiansson, K
    Lederballe-Pedersen, O
    Lindholm, LH
    Nieminen, MS
    Omvik, P
    Oparil, S
    Wedel, H
    [J]. LANCET, 2002, 359 (9311) : 995 - 1003
  • [7] Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA):: a multicentre randomised controlled trial
    Dahlöf, B
    Sever, PS
    Poulter, NR
    Wedel, H
    Beevers, DG
    Caulfield, M
    Collins, R
    Kjeldsen, SE
    Kristinsson, A
    McInnes, GT
    Mehlsen, J
    Nieminen, M
    O'Brien, E
    Östergren, J
    [J]. LANCET, 2005, 366 (9489) : 895 - 906
  • [8] Hyperch olesterolemia stimulates angiotensin peptide synthesis and contributes to atherosclerosis through the AT1A receptor
    Daugherty, A
    Rateri, DL
    Lu, H
    Inagami, T
    Cassis, LA
    [J]. CIRCULATION, 2004, 110 (25) : 3849 - 3857
  • [9] Immunogenetic susceptibility of atherosclerotic stroke - Implications on current and future treatment of vascular inflammation
    DeGraba, TJ
    [J]. STROKE, 2004, 35 (11) : 2712 - 2719
  • [10] Increased endothelial expression of intercellular adhesion molecule-1 in symptomatic versus asymptomatic human carotid atherosclerotic plaque
    DeGraba, TJ
    Sirén, AL
    Penix, L
    McCarron, RM
    Hargraves, R
    Sood, S
    Pettigrew, KD
    Hallenbeck, JM
    [J]. STROKE, 1998, 29 (07) : 1405 - 1410